MedTrace Logo

Study of TRAVATAN in Subjects With Iris Pigmentation Changes

NCT00047554 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 336

Last updated 2013-05-15

No results posted yet for this study

Summary

The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension. To be eligible for the study, these individuals must have experienced an iris pigmentation change while previously dosing with TRAVATAN.

Conditions

Interventions

DRUG

Travoprost, 0.004% ophthalmic solution

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Theresa Landry, PhD · Alcon Research

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2012-06-30
Completion
2012-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00047554 on ClinicalTrials.gov